- Investing.com
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Metrics to compare | MNKI | Peers Peers - average of corresponding metrics from companies closely matching MNKI: AUROPHARMA, WOCKPHARMA, AMRUTANJAN, MOREPENLAB, LUPIN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNKIPeersSector |
---|---|---|---|---|
P/E Ratio | 57.0x | 33.8x | −0.5x | |
PEG Ratio | −11.19 | 1.31 | 0.00 | |
Price/Book | 7.5x | 5.4x | 2.6x | |
Price / LTM Sales | 8.4x | 4.4x | 3.3x | |
Upside (Analyst Target) | 7.1% | 10.8% | 45.1% | |
Fair Value Upside | Unlock | 0.3% | 7.4% | Unlock |